These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
362 related articles for article (PubMed ID: 30423298)
1. KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. Vaseva AV; Blake DR; Gilbert TSK; Ng S; Hostetter G; Azam SH; Ozkan-Dagliyan I; Gautam P; Bryant KL; Pearce KH; Herring LE; Han H; Graves LM; Witkiewicz AK; Knudsen ES; Pecot CV; Rashid N; Houghton PJ; Wennerberg K; Cox AD; Der CJ Cancer Cell; 2018 Nov; 34(5):807-822.e7. PubMed ID: 30423298 [TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer. Wright TD; Raybuck C; Bhatt A; Monlish D; Chakrabarty S; Wendekier K; Gartland N; Gupta M; Burow ME; Flaherty PT; Cavanaugh JE J Cell Biochem; 2020 Feb; 121(2):1156-1168. PubMed ID: 31464004 [TBL] [Abstract][Full Text] [Related]
3. Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells. Diersch S; Wirth M; Schneeweis C; Jörs S; Geisler F; Siveke JT; Rad R; Schmid RM; Saur D; Rustgi AK; Reichert M; Schneider G Oncogene; 2016 Jul; 35(29):3880-6. PubMed ID: 26592448 [TBL] [Abstract][Full Text] [Related]
4. Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. Hayes TK; Neel NF; Hu C; Gautam P; Chenard M; Long B; Aziz M; Kassner M; Bryant KL; Pierobon M; Marayati R; Kher S; George SD; Xu M; Wang-Gillam A; Samatar AA; Maitra A; Wennerberg K; Petricoin EF; Yin HH; Nelkin B; Cox AD; Yeh JJ; Der CJ Cancer Cell; 2016 Jan; 29(1):75-89. PubMed ID: 26725216 [TBL] [Abstract][Full Text] [Related]
5. Activation of either ERK1/2 or ERK5 MAP kinase pathways can lead to disruption of the actin cytoskeleton. Barros JC; Marshall CJ J Cell Sci; 2005 Apr; 118(Pt 8):1663-71. PubMed ID: 15797923 [TBL] [Abstract][Full Text] [Related]
6. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling. Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572 [TBL] [Abstract][Full Text] [Related]
7. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice. Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677 [TBL] [Abstract][Full Text] [Related]
8. Characterization of the MEK5-ERK5 module in human neutrophils and its relationship to ERK1/ERK2 in the chemotactic response. Hii CS; Anson DS; Costabile M; Mukaro V; Dunning K; Ferrante A J Biol Chem; 2004 Nov; 279(48):49825-34. PubMed ID: 15381709 [TBL] [Abstract][Full Text] [Related]
9. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16. Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115 [TBL] [Abstract][Full Text] [Related]
10. ACAGT-007a, an ERK MAPK Signaling Modulator, in Combination with AKT Signaling Inhibition Induces Apoptosis in KRAS Mutant Pancreatic Cancer T3M4 and MIA-Pa-Ca-2 Cells. Khandakar GI; Satoh R; Takasaki T; Fujitani K; Tanabe G; Sakai K; Nishio K; Sugiura R Cells; 2022 Feb; 11(4):. PubMed ID: 35203351 [TBL] [Abstract][Full Text] [Related]
11. MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism. Pereira DM; Simões AE; Gomes SE; Castro RE; Carvalho T; Rodrigues CM; Borralho PM Oncotarget; 2016 Jun; 7(23):34322-40. PubMed ID: 27144434 [TBL] [Abstract][Full Text] [Related]
12. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Waters AM; Khatib TO; Papke B; Goodwin CM; Hobbs GA; Diehl JN; Yang R; Edwards AC; Walsh KH; Sulahian R; McFarland JM; Kapner KS; Gilbert TSK; Stalnecker CA; Javaid S; Barkovskaya A; Grover KR; Hibshman PS; Blake DR; Schaefer A; Nowak KM; Klomp JE; Hayes TK; Kassner M; Tang N; Tanaseichuk O; Chen K; Zhou Y; Kalkat M; Herring LE; Graves LM; Penn LZ; Yin HH; Aguirre AJ; Hahn WC; Cox AD; Der CJ Cell Rep; 2021 Jun; 35(13):109291. PubMed ID: 34192548 [TBL] [Abstract][Full Text] [Related]
13. Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. Ozkan-Dagliyan I; Diehl JN; George SD; Schaefer A; Papke B; Klotz-Noack K; Waters AM; Goodwin CM; Gautam P; Pierobon M; Peng S; Gilbert TSK; Lin KH; Dagliyan O; Wennerberg K; Petricoin EF; Tran NL; Bhagwat SV; Tiu RV; Peng SB; Herring LE; Graves LM; Sers C; Wood KC; Cox AD; Der CJ Cell Rep; 2020 Jun; 31(11):107764. PubMed ID: 32553168 [TBL] [Abstract][Full Text] [Related]
14. Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. Blake DR; Vaseva AV; Hodge RG; Kline MP; Gilbert TSK; Tyagi V; Huang D; Whiten GC; Larson JE; Wang X; Pearce KH; Herring LE; Graves LM; Frye SV; Emanuele MJ; Cox AD; Der CJ Sci Signal; 2019 Jul; 12(590):. PubMed ID: 31311847 [TBL] [Abstract][Full Text] [Related]
16. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells. Liang C; Shi S; Liu M; Qin Y; Meng Q; Hua J; Ji S; Zhang Y; Yang J; Xu J; Ni Q; Li M; Yu X Cancer Res; 2019 Jan; 79(1):133-145. PubMed ID: 30355620 [TBL] [Abstract][Full Text] [Related]
18. The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer. Diehl JN; Klomp JE; Snare KR; Hibshman PS; Blake DR; Kaiser ZD; Gilbert TSK; Baldelli E; Pierobon M; Papke B; Yang R; Hodge RG; Rashid NU; Petricoin EF; Herring LE; Graves LM; Cox AD; Der CJ J Biol Chem; 2021 Nov; 297(5):101335. PubMed ID: 34688654 [TBL] [Abstract][Full Text] [Related]
19. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. Goodwin CM; Waters AM; Klomp JE; Javaid S; Bryant KL; Stalnecker CA; Drizyte-Miller K; Papke B; Yang R; Amparo AM; Ozkan-Dagliyan I; Baldelli E; Calvert V; Pierobon M; Sorrentino JA; Beelen AP; Bublitz N; Lüthen M; Wood KC; Petricoin EF; Sers C; McRee AJ; Cox AD; Der CJ Cancer Res; 2023 Jan; 83(1):141-157. PubMed ID: 36346366 [TBL] [Abstract][Full Text] [Related]
20. Association of PI3K-Akt signaling pathway with digitalis-induced hypertrophy of cardiac myocytes. Liu L; Zhao X; Pierre SV; Askari A Am J Physiol Cell Physiol; 2007 Nov; 293(5):C1489-97. PubMed ID: 17728397 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]